Amarin Corporation plc [NASDAQ: AMRN] stock went on an upward path that rose over 15.07% on Friday, amounting to a one-week price increase of more than 17.48%. The company report on May 24, 2022 that HLS Therapeutics Obtains Public Reimbursement for Vascepa® in Quebec.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
Quebec becomes the first province to reimburse Vascepa for the reduction of cardiovascular risk in patients with established cardiovascular disease.
Private drug plan reimbursement for Vascepa is available in-label for cardiovascular prevention for more than 90% of privately covered lives in Canada.
Over the last 12 months, AMRN stock dropped by -62.25%. The one-year Amarin Corporation plc stock forecast points to a potential upside of 52.94. The average equity rating for AMRN stock is currently 2.90, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $579.60 million, with 397.81 million shares outstanding and 381.31 million shares in the current float. Compared to the average trading volume of 3.91M shares, AMRN stock reached a trading volume of 15098268 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Amarin Corporation plc [AMRN]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for AMRN shares is $3.57 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on AMRN stock is a recommendation set at 2.90. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
JP Morgan have made an estimate for Amarin Corporation plc shares, keeping their opinion on the stock as Underweight, with their previous recommendation back on May 06, 2022. While these analysts kept the previous recommendation, SVB Leerink raised their target price from $10 to $3. The new note on the price target was released on May 05, 2022, representing the official price target for Amarin Corporation plc stock. Previously, the target price had yet another drop from $10 to $3, while H.C. Wainwright kept a Neutral rating on AMRN stock.
The Average True Range (ATR) for Amarin Corporation plc is set at 0.16, with the Price to Sales ratio for AMRN stock in the period of the last 12 months amounting to 1.08. The Price to Book ratio for the last quarter was 1.04, with the Price to Cash per share for the same quarter was set at 1.05.
AMRN Stock Performance Analysis:
Amarin Corporation plc [AMRN] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 17.48. With this latest performance, AMRN shares gained by 7.69% in over the last four-week period, additionally sinking by -52.94% over the last 6 months – not to mention a drop of -62.25% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for AMRN stock in for the last two-week period is set at 46.51, with the RSI for the last a single of trading hit 58.64, and the three-weeks RSI is set at 41.42 for Amarin Corporation plc [AMRN]. The present Moving Average for the last 50 days of trading for this stock 2.4204, while it was recorded at 1.4960 for the last single week of trading, and 3.6567 for the last 200 days.
Insight into Amarin Corporation plc Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Amarin Corporation plc [AMRN] shares currently have an operating margin of +4.15 and a Gross Margin at +78.71. Amarin Corporation plc’s Net Margin is presently recorded at +1.33.
Return on Equity for this stock inclined to 1.19, with Return on Assets sitting at 0.76.
Amarin Corporation plc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.70 and a Current Ratio set at 2.60.
AMRN Stock EPS
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for AMRN. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Amarin Corporation plc go to 38.90%.
Amarin Corporation plc [AMRN] Insider Position Details
There are presently around $223 million, or 34.70% of AMRN stock, in the hands of institutional investors. The top three institutional holders of AMRN stocks are: SARISSA CAPITAL MANAGEMENT LP with ownership of 24,000,000, which is approximately 24.675% of the company’s market cap and around 0.40% of the total institutional ownership; BAKER BROS. ADVISORS LP, holding 21,169,805 shares of the stock with an approximate value of $35.56 million in AMRN stocks shares; and EVERSEPT PARTNERS, LP, currently with $15.09 million in AMRN stock with ownership of nearly -15.068% of the company’s market capitalization.
Positions in Amarin Corporation plc stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 85 institutional holders increased their position in Amarin Corporation plc [NASDAQ:AMRN] by around 20,487,416 shares. Additionally, 94 investors decreased positions by around 25,419,317 shares, while 92 investors held positions by with 86,753,167 shares. The mentioned changes placed institutional holdings at 132,659,900 shares, according to the latest SEC report filing. AMRN stock had 30 new institutional investments in for a total of 8,310,188 shares, while 41 institutional investors sold positions of 21,017,401 shares during the same period.